Functional Progression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study

Functional Progression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study

Background. Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease with rapidly progressive evolution and an unfavorable outcome. Nintedanib (NTD) is an antifibrotic drug that has been shown to be effective in slowing down the progression of the disease. The aim of our study was...

Full description

Bibliographic Details
Main Authors: Barbara Ruaro, Andrea Salotti, Nicolò Reccardini, Stefano Kette, Beatrice Da Re, Salvatore Nicolosi, Umberto Zuccon, Marco Confalonieri, Lucrezia Mondini, Riccardo Pozzan, Michael Hughes, Paola Confalonieri, Francesco Salton
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Pharmaceuticals
Subjects:
idiopathic pulmonary fibrosis (IPF)
interstitial pneumonia
interstitial lung disease (ILD)
Nintedanib (NTD)
pulmonary function tests (PFTs)
high-resolution computed tomography (HRTC)
Online Access:https://www.mdpi.com/1424-8247/17/1/119

Internet

https://www.mdpi.com/1424-8247/17/1/119

Similar Items